Data Sheet (Cat.No.T2413)

TargetMol

FH535

Chemical Properties



CAS No. : 108409-83-2

Formula: C13H10Cl2N2O4S

Molecular Weight: 361.2

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities.
Targets(IC50)	PPAR,Wnt/beta-catenin
In vivo	FH535 inhibits β-catenin/Tcf-mediated transcription and also suppresses the aggregation of co-activator GRIP1 and β-catenin with PPARδ and PPARγ. In cancer cells with elevated or active Wnt/β-catenin pathways, FH535 can inhibit cell proliferation.
Kinase Assay	High-throughput Library Screen: Three copies of the optimized or mutated Tcf-binding element from TOPFLASH or FOPFLASH driving a secreted alkaline phosphatase reporter gene are cloned into pCEP4 plasmid, replacing the cytomegalovirus promoter. The plasmids are transfected into HepG2 cells, and hygromycin-resistant clones are pooled. Library screening is done at 20 μmol/L concentration in HepG2 serum-free media. Hits are tested in the HCT116 cell line for inhibition of TOPFLASH luciferase activity but not for inhibition of a reporter activity controlled from β-actin promoter.
Cell Research	Cell viability is determined by the modified 3H-thymidine incorporation assay. Briefly, cells are plated in 96-well microplates for 24 h and treated in triplicate with various concentrations of the test compound. After 48 h of compound exposure, the cells are incubated for an additional 48 h in compound-free medium. The cells are then incubated in medium containing 3H-thymidine for 24 h, washed and mixed with the scintillant in the 96-well plate. Individual wells are counted with a 96-well scintillation counter and the LC50 is calculated.(Only for Reference)

Solubility Information

Solubility	DMSO: 65 mg/mL (179.96 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.54 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7685 mL	13.8427 mL	27.6855 mL
5 mM	0.5537 mL	2.7685 mL	5.5371 mL
10 mM	0.2769 mL	1.3843 mL	2.7685 mL
50 mM	0.0554 mL	0.2769 mL	0.5537 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Handeli S, et al. Mol Cancer Ther. 2008, 7(3), 521-529.
Wang C, Wang T, He Q, et al.Inhibition of the canonical Wnt/β-catenin pathway interferes with macropinocytosis to suppress pseudorabies virus proliferation.Veterinary Microbiology.2025: 110373.
Polk WW. Int J Toxicol. 2012, 31(4), 380-389.
Gedaly R, et al. PLoS One. 2014, 9(6), e99272.